Enlivex to Present at Upcoming Investor and Media Conferences

Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following investor and media conferences in September. 

H.C. Wainwright 24^th Annual Global Investment Conference

Baird’s 2022 Global Healthcare Conference

Cantor Cell and Genetic Medicines Conference

Company management will be available for 1×1 investor meetings during the Cantor and H.C. Wainwright events. Those interested in requesting a meeting during the conferences should contact their respective event representative.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit https://enlivex.com/.

ENLIVEX CONTACT                                                                            
Shachar Shlosberger, CFO                                                                    
Enlivex Therapeutics, Ltd.                                                                      
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com